Skip to main content
OpenTrials
Completed

NCT Number: NCT07566416

MIRABEGRON AND UAS OUTCOMES DURING RIRS

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Stone Calculi Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Calculi Kidney Diseases Male Urogenital Diseases Nephrolithiasis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Retrograde Intrarenal Surgery (RIRS) Ureteral Access Sheath Urinary Calculi Urogenital Diseases Urolithiasis Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Training and Research Hospital

Ankara, Altındağ, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients scheduled for RIRS due to kidney stones

Exclusion criteria

  • preoperative ureteral stenting,
  • ureteral strictures, history of ureteral or bladder surgery,
  • anatomical abnormalities of the urinary tract,
  • active urinary tract infection,
  • pregnancy,
  • uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg),
  • use of medications affecting ureteral smooth muscle tone

Treatment and study plan

Retrograde Intrarenal Surgery

Procedure

In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones. No additional intervention was performed beyond the routine surgical procedure.

Primary outcomes

  1. Ureteral access sheath insertion rate

    Time frame: From January 2018 to October 2021

Secondary outcomes

  1. Ureteral injury rate

    Time frame: From January 2018 to October 2024

Sponsors and collaborators

Lead sponsor

Ankara Training and Research Hospital

Other

Registry information

Official study title

THE EFFECT OF PREOPERATIVE MIRABEGRON ON URETERAL ACCESS SHEATH INSERTION SUCCESS AND URETERAL INJURY DURING RETROGRADE INTRARENAL SURGERY: A RETROSPECTIVE COMPARATIVE STUDY

Important dates

Study start
2018
Primary completion
2021
Study completion
2025
First posted
May 5, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.